PepGen Inc. (NASDAQ:PEPG) Shares Bought by Deutsche Bank AG

Deutsche Bank AG boosted its position in shares of PepGen Inc. (NASDAQ:PEPG) by 442.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 44,735 shares of the company’s stock after acquiring an additional 36,489 shares during the period. Deutsche Bank AG owned about 0.14% of PepGen worth $170,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PEPG. China Universal Asset Management Co. Ltd. purchased a new stake in shares of PepGen during the 4th quarter worth approximately $26,000. Corton Capital Inc. purchased a new stake in shares of PepGen during the 4th quarter worth approximately $68,000. Bank of America Corp DE lifted its position in shares of PepGen by 54.7% during the 4th quarter. Bank of America Corp DE now owns 53,868 shares of the company’s stock worth $204,000 after buying an additional 19,056 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of PepGen by 26.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 57,102 shares of the company’s stock worth $216,000 after buying an additional 11,870 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of PepGen by 103.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company’s stock worth $375,000 after buying an additional 50,200 shares during the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Price Performance

PEPG stock opened at $1.44 on Tuesday. The company has a fifty day moving average price of $1.41 and a 200 day moving average price of $2.45. PepGen Inc. has a 12 month low of $0.88 and a 12 month high of $19.30. The company has a market cap of $47.12 million, a price-to-earnings ratio of -0.48 and a beta of 1.39.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.20). As a group, analysts anticipate that PepGen Inc. will post -2.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price objective on shares of PepGen from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 29th.

Insider Activity at PepGen

In other news, CEO James G. Mcarthur acquired 41,500 shares of the company’s stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.15 per share, with a total value of $47,725.00. Following the purchase, the chief executive officer now owns 103,913 shares of the company’s stock, valued at $119,499.95. This represents a 66.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired a total of 59,875 shares of company stock worth $71,610 in the last 90 days. 5.20% of the stock is owned by insiders.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.